Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms

(2021) Nicole Koutsodendris et al.   Annual Review of Pathology-Mechanisms of Disease

Biomarkers for neurodegenerative diseases

(2021) Oskar Hansson   NATURE MEDICINE

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

(2021) Itziar de Rojas et al.   Nature Communications

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

APOEε4 potentiates the relationship between amyloid-β and tau pathologies

(2020) Joseph Therriault et al.   MOLECULAR PSYCHIATRY

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

(2020) Elles Konijnenberg et al.   Alzheimers Research & Therapy

Sex differences in CSF biomarkers vary by Alzheimer’s disease stage and APOE ε4 genotype

(2020) Rosha Babapour Mofrad et al.   NEUROLOGY

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

(2020) Thomas K. Karikari et al.   Alzheimers & Dementia

APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid

(2020) Miles Berger et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

(2019) Isabelle Bos et al.   Alzheimers & Dementia

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

(2017) Piotr Lewczuk et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

(2017) Lutz Frölich et al.   Alzheimers Research & Therapy

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Association of APOE with tau-tangle pathology with and without β-amyloid

(2016) Jose M. Farfel et al.   NEUROBIOLOGY OF AGING

Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects

(2015) Jon B. Toledo et al.   BRAIN

Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage

(2015) Stephanie J. B. Vos et al.   BRAIN

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)

(2014) Shannon Risacher   Frontiers in Aging Neuroscience

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease

(2014) Ronald Lautner et al.   JAMA Psychiatry

Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease

(2013) D. M. Holtzman et al.   Cold Spring Harbor Perspectives in Medicine

Injury markers predict time to dementia in subjects with MCI and amyloid pathology

(2012) I. A. van Rossum et al.   NEUROLOGY

Apolipoprotein E in Alzheimer's disease and other neurological disorders

(2011) Philip B Verghese et al.   LANCET NEUROLOGY

Effect of APOE on biomarkers of amyloid load and neuronal pathology in AD

(2009) Prashanthi Vemuri et al.   ANNALS OF NEUROLOGY

APOEpredicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

(2009) John C. Morris et al.   ANNALS OF NEUROLOGY

Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment

(2009) Johannes Kornhuber et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS